NCT02603705

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 281 (actual)
• Sponsor: Egalet Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Conditions

• Moderate-to-severe Chronic Noncancer Pain

Interventions

Type	Name	Description
DRUG	Oxycodone extended-release

Timeline

• Start date: 2016-03-07
• Primary completion: 2017-06-15
• Completion: 2017-06-15
• First posted: 2015-11-13
• Last updated: 2018-03-05

Locations

39 sites across 1 country: United States